Literature DB >> 28273716

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

Matthias A Oberli, Andreas M Reichmuth, J Robert Dorkin, Michael J Mitchell, Owen S Fenton, Ana Jaklenec, Daniel G Anderson1, Robert Langer1, Daniel Blankschtein.   

Abstract

The induction of a strong cytotoxic T cell response is an important prerequisite for successful immunotherapy against many viral diseases and tumors. Nucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. The intracellular delivery of mRNA vaccines to the cytosol of antigen presenting immune cells is still not sufficiently well understood. Here, we report on the development of a lipid nanoparticle formulation for the delivery of mRNA vaccines to induce a cytotoxic CD 8 T cell response. We show transfection of dendritic cells, macrophages, and neutrophils. The efficacy of the vaccine was tested in an aggressive B16F10 melanoma model. We found a strong CD 8 T cell activation after a single immunization. Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice. The immune response can be further increased by the incorporation of the adjuvant LPS. In conclusion, the lipid nanoparticle formulation presented here is a promising vector for mRNA vaccine delivery, one that is capable of inducing a strong cytotoxic T cell response. Further optimization, including the incorporation of different adjuvants, will likely enhance the potency of the vaccine.

Entities:  

Keywords:  cancer immunotherapy; cytotoxic T cells; immune response; lipid nanoparticles; mRNA; vaccines

Mesh:

Substances:

Year:  2016        PMID: 28273716      PMCID: PMC5523404          DOI: 10.1021/acs.nanolett.6b03329

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  51 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

Review 2.  Innate immune pattern recognition: a cell biological perspective.

Authors:  Sky W Brubaker; Kevin S Bonham; Ivan Zanoni; Jonathan C Kagan
Journal:  Annu Rev Immunol       Date:  2015-01-02       Impact factor: 28.527

3.  Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.

Authors:  Sara R Pedersen; Maria R Sørensen; Søren Buus; Jan P Christensen; Allan R Thomsen
Journal:  J Immunol       Date:  2013-09-09       Impact factor: 5.422

Review 4.  Non-viral vectors for gene-based therapy.

Authors:  Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson
Journal:  Nat Rev Genet       Date:  2014-07-15       Impact factor: 53.242

5.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Authors:  Yizhou Dong; Kevin T Love; J Robert Dorkin; Sasilada Sirirungruang; Yunlong Zhang; Delai Chen; Roman L Bogorad; Hao Yin; Yi Chen; Arturo J Vegas; Christopher A Alabi; Gaurav Sahay; Karsten T Olejnik; Weiheng Wang; Avi Schroeder; Abigail K R Lytton-Jean; Daniel J Siegwart; Akin Akinc; Carmen Barnes; Scott A Barros; Mary Carioto; Kevin Fitzgerald; Julia Hettinger; Varun Kumar; Tatiana I Novobrantseva; June Qin; William Querbes; Victor Koteliansky; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 6.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

7.  Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

Authors:  Charlotte Pollard; Joanna Rejman; Winni De Haes; Bernard Verrier; Ellen Van Gulck; Thomas Naessens; Stefaan De Smedt; Pieter Bogaert; Johan Grooten; Guido Vanham; Stefaan De Koker
Journal:  Mol Ther       Date:  2012-09-25       Impact factor: 11.454

8.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

Authors:  James Heyes; Lorne Palmer; Kaz Bremner; Ian MacLachlan
Journal:  J Control Release       Date:  2005-10-03       Impact factor: 9.776

Review 9.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 10.  Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.

Authors:  C Trumpfheller; M P Longhi; M Caskey; J Idoyaga; L Bozzacco; T Keler; S J Schlesinger; R M Steinman
Journal:  J Intern Med       Date:  2012-01-04       Impact factor: 8.989

View more
  146 in total

1.  Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.

Authors:  Hongxia Zhang; Xinru You; Xiaojuan Wang; Lei Cui; Zining Wang; Feifei Xu; Mengyun Li; Zhenggang Yang; Jinyun Liu; Peng Huang; Yang Kang; Jun Wu; Xiaojun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

2.  Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.

Authors:  Toni K Choueiri; Michael B Atkins; Ziad Bakouny; Maria I Carlo; Charles G Drake; Eric Jonasch; Payal Kapur; Bryan Lewis; W Marston Linehan; Michael J Mitchell; Sumanta K Pal; Kevin Pels; Susan Poteat; W Kimryn Rathmell; Brian I Rini; Sabina Signoretti; Nizar Tannir; Robert Uzzo; Christopher G Wood; Hans J Hammers
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

Review 3.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 4.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 5.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 6.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

7.  Preparation and Optimization of Lipid-Like Nanoparticles for mRNA Delivery.

Authors:  Bin Li; Yizhou Dong
Journal:  Methods Mol Biol       Date:  2017

Review 8.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 9.  Transfection by cationic gemini lipids and surfactants.

Authors:  M Damen; A J J Groenen; S F M van Dongen; R J M Nolte; B J Scholte; M C Feiters
Journal:  Medchemcomm       Date:  2018-07-17       Impact factor: 3.597

Review 10.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.